Background To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily
(bid) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Background: The PARALLEL-HF study assessed the efficacy and safety of
sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Background The effect of sacubitril-valsartan in heart failure patients with mid-range
(HFmEF) and preserved (HFpEF) ejection fractions remains unclear. This study aimed to …

Background: The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …

Objectives: The aim of this study was to assess the prevalence and variation in angiotensin
receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart …

Background Heart failure (HF) is a growing public health problem. Sacubitril/valsartan is
now recommended to be used in persistently symptomatic patients with left ventricular …

Introduction Sacubitril/valsartan has been established as an effective treatment for heart
failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …